Anika Therapeutics, Inc.

ANIK · XNAS

CIK 898437fmd_1SDRRA88SXFE50XYMXHMQS8GWTManufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard

Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	103	113	106	115	130	148	114	121	120	113
Cost of revenue	24	27	31	29	61	65	41	38	44	49
Gross profit	79	86	74	86	69	83	73	83	76	64
Realized investment gains (losses)	–	–	0	0	(0)	–	–	–	–	–
Research and development	11	19	18	17	23	27	18	22	26	26
Selling, general and administrative	18	22	34	35	60	74	51	60	56	49
Operating income	51	46	22	34	(28)	3	4	1	(5)	(11)
Income before taxes	51	46	23	36	(29)	2	4	3	(3)	(9)
Income tax expense	18	14	4	9	(5)	(2)	2	7	6	1
Net income from continuing operations	33	32	19	27	(24)	4	2	(3)	(9)	(10)
Net income	33	32	19	27	(24)	4	(15)	(83)	(56)	(11)